Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04063592 · ClinicalTrials.gov registry record · NA

AMI Construction in Lower Extremity Residual Limbs

A NA study of Amputation, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
NA
Development phase
26
Enrollment target
3
Study locations

NCT04063592 is a NA study of Amputation that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 26 participants, below the 132-participant average among 65 other Amputation trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04063592, a NA study of Amputation, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
NA
Development phase
26 participants
Enrollment target
3
Study locations

Study Summary

This study will involve the development of a novel approach to lower extremity residual limb surgical revision that offers the promise of augmenting volitional motor control, restore proprioception and reverse atrophy

Conditions Studied

Interventions

  • PROCEDURE Residual limb revision

Study Locations (3)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Massachusetts Institute of Technology - Cambridge

Maryland

  • Walter Reed National Military Medical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2020-02-24
Est. Completion 2026-09-30
Phase NA

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT04063592

The ClinicalTrials.gov registry entry for NCT04063592 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 65 other Amputation trials with a reported enrollment target (80% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Amputation appearing as the primary indexed condition, and to 1 intervention - of which Residual limb revision is the first listed.

NCT04063592 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Maryland.

Frequently Asked Questions

What is clinical trial NCT04063592 about?

NCT04063592 is a clinical study titled "AMI Construction in Lower Extremity Residual Limbs". This study will involve the development of a novel approach to lower extremity residual limb surgical revision that offers the promise of augmenting volitional motor control, restore proprioception and reverse atrophy

What is the current status of trial NCT04063592?

This trial is currently recruiting. It is a NA study. The enrollment target is 26 participants. The study started on 2020-02-24. Estimated completion is 2026-09-30.

What conditions does trial NCT04063592 study?

This clinical trial studies the following conditions: Amputation.

What interventions are being tested in trial NCT04063592?

The interventions under investigation include: Residual limb revision (PROCEDURE).

Who is sponsoring clinical trial NCT04063592?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04063592 being conducted?

This trial has 3 study locations across Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amputation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.